These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29735308)

  • 21. Elbasvir-grazoprevir: A new direct-acting antiviral combination for hepatitis C.
    Karaoui LR; Mansour H; Chahine EB
    Am J Health Syst Pharm; 2017 Oct; 74(19):1533-1540. PubMed ID: 28947524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.
    Yao Y; Yue M; Wang J; Chen H; Liu M; Zang F; Li J; Zhang Y; Huang P; Yu R
    Can J Gastroenterol Hepatol; 2017; 2017():8186275. PubMed ID: 28164081
    [No Abstract]   [Full Text] [Related]  

  • 23. Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4.
    Al-Salama ZT; Deeks ED
    Drugs; 2017 May; 77(8):911-921. PubMed ID: 28417245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial.
    Boerekamps A; De Weggheleire A; van den Berk GE; Lauw FN; Claassen MAA; Posthouwer D; Bierman WF; Hullegie SJ; Popping S; van de Vijver DACM; Dofferhoff ASM; Kootstra GJ; Leyten EM; den Hollander J; van Kasteren ME; Soetekouw R; Ammerlaan HSM; Schinkel J; Florence E; Arends JE; Rijnders BJA
    Lancet Gastroenterol Hepatol; 2019 Apr; 4(4):269-277. PubMed ID: 30660617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects.
    Hsieh YC; Lin CL; Hung CH; Chen CH; Tung SY; Lin CY; Hu TH; Lu SN; Chien RN; Sheen IS
    J Viral Hepat; 2020 May; 27(5):505-513. PubMed ID: 32039536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3.
    Yeh WW; Fraser IP; Jumes P; Petry A; Lepeleire I; Robberechts M; Reitmann C; Van Dyck K; Huang X; Guo Z; Panebianco D; Nachbar RB; O'Mara E; Wagner JA; Butterton JR; Dutko FJ; Moiseev V; Kobalava Z; Hüser A; Visan S; Schwabe C; Gane E; Popa S; Ghicavii N; Uhle M; Wagner F
    Clin Ther; 2018 May; 40(5):704-718.e6. PubMed ID: 29703432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.
    Zamor PJ; Vierling J; Ghalib R; Luketic V; Ravendhran N; Balart L; Robertson M; Hwang P; Hanna GJ; Nguyen BY; Barr E; Talwani R; Pearlman B
    Am J Gastroenterol; 2018 Jun; 113(6):863-871. PubMed ID: 29695828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
    Braun DL; Hampel B; Kouyos R; Nguyen H; Shah C; Flepp M; Stöckle M; Conen A; Béguelin C; Künzler-Heule P; Nicca D; Schmid P; Delaloye J; Rougemont M; Bernasconi E; Rauch A; Günthard HF; Böni J; Fehr JS;
    Clin Infect Dis; 2019 Feb; 68(4):569-576. PubMed ID: 30107485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort.
    Hernández-Conde M; Fernández I; Perelló C; Gallego A; Bonacci M; Pascasio JM; Romero-Gómez M; Llerena S; Fernández-Rodríguez C; Castro Urda JL; García Buey L; Carmona I; Morillas RM; García ND; Gea F; Carrión JA; Castellote J; Moreno-Planas JM; Piqueras Alcol B; Molina E; Diago M; Montoliu S; de la Vega J; Menéndez F; Sánchez Ruano JJ; García-Samaniego J; Rosales-Zabal JM; Anton MD; Badia E; Souto-Rodríguez R; Salmeron FJ; Fernández-Bermejo M; Figueruela B; Moreno-Palomares JJ; Calleja JL
    J Viral Hepat; 2019 Jan; 26(1):55-64. PubMed ID: 30265418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
    Asselah T; Reesink H; Gerstoft J; de Ledinghen V; Pockros PJ; Robertson M; Hwang P; Asante-Appiah E; Wahl J; Nguyen BY; Barr E; Talwani R; Serfaty L
    Liver Int; 2018 Sep; 38(9):1583-1591. PubMed ID: 29461687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection.
    Ahmed H; Abushouk AI; Menshawy A; Attia A; Mohamed A; Negida A; Abdel-Daim MM
    Ann Hepatol; 2018; 17(1):18-32. PubMed ID: 29311409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.
    Zarębska-Michaluk D; Jaroszewicz J; Buczyńska I; Simon K; Lorenc B; Tudrujek-Zdunek M; Tomasiewicz K; Sitko M; Garlicki A; Janczewska E; Dybowska D; Halota W; Pawłowska M; Pabjan P; Mazur W; Czauż-Andrzejuk A; Berak H; Horban A; Socha Ł; Klapaczyński J; Piekarska A; Blaszkowska M; Belica-Wdowik T; Dobracka B; Tronina O; Deroń Z; Białkowska-Warzecha J; Laurans Ł; Flisiak R
    J Gastroenterol Hepatol; 2020 Jul; 35(7):1238-1246. PubMed ID: 31734959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
    Foster GR; Agarwal K; Cramp ME; Moreea S; Barclay S; Collier J; Brown AS; Ryder SD; Ustianowski A; Forton DM; Fox R; Gordon F; Rosenberg WM; Mutimer DJ; Du J; Gilbert CL; Asante-Appiah E; Wahl J; Robertson MN; Barr E; Haber B
    Hepatology; 2018 Jun; 67(6):2113-2126. PubMed ID: 29473975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.
    Suda G; Kurosaki M; Itakura J; Izumi N; Uchida Y; Mochida S; Hasebe C; Abe M; Haga H; Ueno Y; Masakane I; Abe K; Takahashi A; Ohira H; Furuya K; Baba M; Yamamoto Y; Kobayashi T; Kawakami A; Kumagai K; Terasita K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
    J Gastroenterol; 2019 Jan; 54(1):78-86. PubMed ID: 30019127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C.
    Carrion AF; Martin P
    Expert Opin Drug Saf; 2016 Jun; 15(6):883-90. PubMed ID: 27091555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
    Dore GJ; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Grebely J; Howe AY; Gendrano IN; Chen E; Huang HC; Dutko FJ; Nickle DC; Nguyen BY; Wahl J; Barr E; Robertson MN; Platt HL;
    Ann Intern Med; 2016 Nov; 165(9):625-634. PubMed ID: 27537841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection.
    Corman S; Elbasha EH; Michalopoulos SN; Nwankwo C
    Value Health; 2017 Sep; 20(8):1110-1120. PubMed ID: 28964443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study.
    Jacobson IM; Poordad F; Firpi-Morell R; Everson GT; Verna EC; Bhanja S; Hwang P; Caro L; Robertson M; Charles ED; Platt H
    Clin Transl Gastroenterol; 2019 Apr; 10(4):e00007. PubMed ID: 30939489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.
    El Kassas M; Elbaz T; Abd El Latif Y; Esmat G
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1413-1421. PubMed ID: 27603877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
    Sperl J; Horvath G; Halota W; Ruiz-Tapiador JA; Streinu-Cercel A; Jancoriene L; Werling K; Kileng H; Koklu S; Gerstoft J; Urbanek P; Flisiak R; Leiva R; Kazenaite E; Prinzing R; Patel S; Qiu J; Asante-Appiah E; Wahl J; Nguyen BY; Barr E; Platt HL
    J Hepatol; 2016 Dec; 65(6):1112-1119. PubMed ID: 27542322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.